Confirmed disability progression as a marker of permanent disability in multiple sclerosis

S Sharmin; F Bovis; C Malpas; D Horakova; E Havrdova; G Izquierdo; S Eichau; M Trojano; A Prat; M Girard; P Duquette; M Onofrj; A Lugaresi; F Grand'Maison; P Grammond; P Sola; D Ferraro; M Terzi; O Gerlach; R Alroughani; C Boz; V Shaygannejad; V van Pesch; E Cartechini; L Kappos; J Lechner-Scott; R Bergamaschi; R Turkoglu; C Solaro; G Iuliano; F Granella; B Van Wijmeersch; D Spitaleri; M Slee; P McCombe; J Prevost; R Ampapa; S Ozakbas; J Sanchez-Menoyo; A Soysal; S Vucic; T Petersen; K de Gans; E Butler; S Hodgkinson; Y Sidhom; R Gouider; E Cristiano; T Castillo-Triviño; M Saladino; M Barnett; F Moore; C Rozsa; B Yamout; O Skibina; A van der Walt; K Buzzard; O Gray; S Hughes; AP Sempere; B Singhal; Y Fragoso; C Shaw; A Kermode; B Taylor; M Simo; N Shuey; T Al-Harbi; R Macdonell; JA Dominguez; T Csepany; C Sirbu; MP Sormani; H Butzkueven; T Kalincik

Journal article

Confirmed disability progression as a marker of permanent disability in multiple sclerosis

S Sharmin, F Bovis, C Malpas, D Horakova, E Havrdova, G Izquierdo, S Eichau, M Trojano, A Prat, M Girard, P Duquette, M Onofrj, A Lugaresi, F Grand'Maison, P Grammond, P Sola, D Ferraro, M Terzi, O Gerlach, R Alroughani Show all

European Journal of Neurology | Published : 2022

DOI: 10.1111/ene.15406

Download PDF

Abstract

Background and purpose: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of resulting in sustained long-term disability worsening. Methods: In total, 14,802 6-month confirmed disability progression events were identified in 8741 patients from the global MSBase registry. For each 6-month confirmed progression event (13,321 in the development and 1481 in the validation cohort), a sustained progression score was calculated based on t..

View full abstract

University of Melbourne Researchers

Sifat Sharmin Author

Charles Malpas Author

Neil Shuey Author

Richard MacDonell Author

Related Projects (3)

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

BIOMARKERS TO PREVENT DISABILITY IN MULTIPLE SCLEROSIS

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This study was funded by the NHMRC (grants 1129189 and 1157717 and fellowship 1140766). The MSBase Foundation is a not-for-profit organization that receives support from Merck, Biogen, Novartis, Roche, Bayer Schering, Sanofi Genzyme and Teva Pharmaceutical Industries. The study was conducted separately and apart from the guidance of the sponsors.